The reports were created using data from the GOED Clinical Study Database tracking human clinical studies on EPA and DHA omega-3 fatty acids.
Two new reports from omega-3 association the Global Organization for EPA and DHA Omega-3s (GOED; Salt Lake City, UT) report on the clinical research landscape examining the link between EPA and DHA omega-3 fatty acids and skin health conditions dermatitis and psoriasis. The reports were created using data from the GOED Clinical Study Database tracking human clinical studies on EPA and DHA omega-3 fatty acids.
“Both reports offer valuable insights, including the background of the conditions, the number and type of articles published, commonly found biomarkers, key influencers in the field, and suggested next research steps,” GOED’s press release states. On its website, it further adds, “These two skin conditions”—dermatitis and psoriasis—“are stand-ins for common omega-3 skin health marketing claims like ‘promotes glowing, healthy, smooth skin,’ which don’t match any scientifically recognized clinical outcomes.”
GOED’s Clinical Study Database captures data on more than 4,500 human clinical studies on EPA and DHA omega-3s.
Cracking the code: Advancements in calcium absorption and nutritional understanding
July 23rd 2024Recent research conducted by ILSI U.S. and Canada – a global, nonprofit federation dedicated to advancing precompetitive research in the food, nutrition and health realms – and partially funded by Balchem, has shed light on how to improve predictions of Ca bioavailability across different food matrices.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.